Procedure Deep-Dive · November 16, 2026

Pemphigus Vulgaris and Cosmetic Procedures: Mouth Blisters, Lip Filler, Lasers, Peels, Facelifts, Rituximab, Steroids, and Wound Healing

Pemphigus is the autoimmune disease in which the immune system attacks the glue that holds skin cells together. The result is fragile skin and painful erosions in the mouth, and it raises a set of cosmetic questions most practices rarely face: whether a peel or laser can provoke new blisters, whether surgical tape can tear skin, what remission has to look like before anything elective, and how to time a facelift around rituximab and steroids.

By The Editorial Desk

18 min read

A man in his fifties with short salt-and-pepper hair and a gray beard, wearing a dark green crew-neck sweater, seated at a wooden table beside a tall window, one hand resting on folded papers next to a glass of water, gazing out the window with a thoughtful expression

He is 54 and arrives with a tidy list. He wants his jowls and neck addressed, he wants something done about the sun damage on his cheeks and forehead, and he has a note from his wife suggesting lip filler, which he finds funny. Under medical history he has written "mouth sores, seeing a dentist." Asked about it, he explains that for most of the year he has had raw, painful patches inside his cheeks and along his gums that do not heal. His dentist treated it as gum disease, then as a reaction to toothpaste. He has lost weight because eating hurts. Lately a few crusted, weeping spots have appeared on his scalp and chest that he assumed were from a new shampoo. He would like to schedule the facelift for spring.

A careful surgeon hears that history and stops talking about jowls. Persistent, painful mouth erosions that will not heal, followed months later by fragile, crusting spots on the scalp and trunk, is the classic sequence of pemphigus vulgaris, a rare autoimmune blistering disease that is regularly missed for months by the very clinicians patients see first. It matters to cosmetic medicine for an unusual reason. Pemphigus attacks the structures that hold skin cells to each other, so the skin itself becomes mechanically fragile, and many of the procedures in a cosmetic practice work by deliberately injuring the surface and asking it to heal. This piece covers what pemphigus is, what remission must look like before anything elective, how lips, lasers, and peels fit in, what changes in the operating room, and how rituximab and steroids shape the calendar.

Pemphigus and cosmetic procedures: what the disease is and why the mouth comes first

The short answer: Pemphigus vulgaris is an autoimmune disease in which antibodies attack desmogleins, the proteins that bind skin cells together, causing fragile blisters and painful erosions that usually begin in the mouth, and it must be diagnosed and controlled before any cosmetic procedure is considered.

The outer layer of skin and the lining of the mouth are built from cells held together by tiny rivets called desmosomes. Two of the proteins in those rivets, desmoglein 3 and desmoglein 1, are the targets in pemphigus. When antibodies bind them, the cells separate from each other in a process pathologists call acantholysis, and the tissue splits within the epidermis. The blisters that form are thin-roofed and break easily, leaving raw erosions rather than the tense, intact blisters people picture. Desmoglein 3 dominates in the mouth, and desmoglein 1 dominates in the outer skin, which explains the usual sequence: patients whose antibodies target desmoglein 3 alone get mouth disease first, and the skin follows when antibodies to desmoglein 1 develop as well.

Pemphigus is rare. A 2019 analysis of United States insurance data estimated a prevalence of roughly five per 100,000 adults. It most often begins between the ages of 40 and 60, the same window in which many people first consider a facelift, eyelid surgery, or resurfacing. It is more common in people of Ashkenazi Jewish, Mediterranean, Middle Eastern, and South Asian ancestry, reflecting known genetic associations. Before corticosteroids became available in the 1950s, pemphigus vulgaris was fatal in most patients. It is now a treatable chronic disease, and many patients reach long remissions, but its treatment carries its own risks.

The forms a cosmetic practice may meet:

  • Pemphigus vulgaris. The most common form in the United States. Painful erosions on the gums, inner cheeks, palate, tongue, and lips, often for months before any skin lesions appear. The throat, nose, eyes, and genitals can also be involved.
  • Pemphigus foliaceus. Antibodies to desmoglein 1 only. The split is very superficial, so the skin shows scaly, crusted, flaky patches rather than obvious blisters, often on the face, scalp, chest, and upper back. The mouth is spared. On the face it is easily mistaken for seborrheic dermatitis or a rosacea flare, the territory covered in the piece on facial redness and vascular lasers.
  • Drug-induced pemphigus. Certain medications, classically those containing a thiol group such as penicillamine and captopril, can trigger or unmask the disease. Most cases improve after the drug is stopped, though some persist.
  • Paraneoplastic pemphigus. A distinct and serious disease associated with lymphomas, chronic lymphocytic leukemia, and Castleman disease, with severe, stubborn mouth and lip erosions and a risk of lung involvement. A patient with relentless lip erosions and an unexplained lymphoma history needs an oncologic workup, not a cosmetic one.

The diagnosis is made with a biopsy from the edge of a fresh lesion, which shows the characteristic split, plus a second biopsy of nearby normal-looking skin or mucosa for direct immunofluorescence, which shows antibodies coating the cell surfaces in a fishnet pattern. Blood tests that measure antibodies to desmoglein 1 and desmoglein 3 support the diagnosis and, in many patients, rise and fall loosely with disease activity. The bedside clue is the Nikolsky sign: firm sideways pressure on apparently normal skin near active disease can shear off the top layer. That sign is the single most useful thing for a cosmetic surgeon to understand, because it means that friction, shear, and adhesive tape are not neutral events for this skin.

The diagnostic delay is the real problem. Oral pemphigus looks like aphthous ulcers, herpes, gum disease, a denture sore, or oral lichen planus, and studies of patients with pemphigus have repeatedly found that many saw several clinicians, often dentists, before the correct diagnosis was made. A patient who mentions mouth sores lasting more than a few weeks during a consultation for lip filler or a lip lift should be referred for evaluation before anyone touches the lips.

Remission is the gate: what controlled pemphigus means before anything elective

The short answer: Elective cosmetic procedures belong in a period of documented, sustained remission, ideally off treatment or on minimal therapy, as confirmed by the treating dermatologist, and never during active disease, during an early steroid taper, or in the weeks around a rituximab infusion.

Pemphigus experts use specific language for disease status, and patients should learn it because it is the language that decides whether a procedure is reasonable. An international consensus defined a series of milestones: control of disease activity (no new lesions and existing ones starting to heal), the end of the consolidation phase (no new lesions for at least two weeks and most lesions healed), complete remission on therapy, complete remission on minimal therapy (no lesions while taking a low dose of prednisone, generally 10 mg a day or less, and/or minimal adjuvant medication), and complete remission off therapy. Disease severity is often tracked with a scoring system called the Pemphigus Disease Area Index. These definitions exist because the course of pemphigus is uneven, and "it's much better" can mean anything from almost healed to quietly smoldering in the mouth.

Treatment has changed substantially in the last decade. In 2017, a French randomized trial called Ritux 3, published in The Lancet, compared rituximab plus a short course of prednisone against prednisone alone as first-line treatment in newly diagnosed pemphigus. At two years, 89 percent of patients in the rituximab group were in complete remission off therapy, compared with 34 percent in the prednisone-only group, and the rituximab group had fewer serious steroid-related side effects. In 2018 the FDA approved rituximab for moderate to severe pemphigus vulgaris in adults, the first biologic approved for the disease. Current European and international guidelines recommend rituximab as a first-line option for moderate to severe disease, often with corticosteroids at the start, and with mycophenolate or azathioprine as steroid-sparing alternatives or additions. Intravenous immunoglobulin and plasma exchange are reserved for refractory or severe cases.

What this means for scheduling:

  • Active disease or early treatment is a hard stop. New lesions, erosions that are not healing, or a steroid dose still being actively tapered from high levels all mean the immune process is not under control and wound healing is impaired. No elective procedure belongs here.
  • Relapse often follows a predictable signal. Rising desmoglein antibody levels and a return of B cells after rituximab can precede a clinical relapse. A dermatologist who is monitoring these values can say whether the next few months look stable or uncertain, which is exactly the question a surgeon needs answered.
  • Sustained remission is the window. There is no universally agreed waiting period, but most dermatologists would want months of complete remission, on minimal therapy or none, before an elective operation, and longer before any procedure that deliberately injures the skin surface. The decision is individual and belongs with the specialist who knows the patient's disease history and antibody trend.
  • Mouth disease counts. Remission means remission everywhere, including the mouth. A patient with clear skin and a few persistent erosions on the gums is not in remission, and that matters for intubation and for any perioral work.

The point is not to keep patients with pemphigus away from cosmetic care forever. It is to put the procedure in the right season. A facelift performed during a stable remission, with a clear medication plan, is a very different operation from the same facelift performed four months into a steroid taper. The broader principles of operating around immune-mediated disease are covered in the piece on cosmetic surgery with autoimmune disease, and pemphigus follows them with a few sharper edges.

Lips, mouth, and lasers: why procedures that injure the surface are the hardest call

The short answer: Procedures that work by wounding the epidermis or the mucosa, including ablative lasers, medium and deep peels, dermabrasion, microneedling, and perioral injections, carry the highest theoretical risk in pemphigus, because trauma has been reported to trigger new lesions and the healing process depends on exactly the cell-to-cell adhesion the disease attacks.

Cosmetic resurfacing is, at bottom, a controlled injury. A chemical peel or laser removes or damages the outer layers of skin and relies on the surrounding keratinocytes to migrate in, attach to one another, and rebuild a smooth surface. In pemphigus, that rebuilding depends on desmosomes that the patient's own antibodies are targeting. The medical literature includes case reports of pemphigus lesions appearing or flaring at sites of burns, radiation, ultraviolet exposure, surgery, and laser and peel procedures, a phenomenon sometimes described as a Koebner-type response. These are individual reports, not large studies, and many patients in deep remission undoubtedly tolerate skin procedures without trouble. But the asymmetry of risk is real: a flare provoked across the whole face by a resurfacing treatment would be both painful and medically significant.

A reasonable hierarchy, to be confirmed with the treating dermatologist:

  • Neurotoxins. Small-volume injections with fine needles, little surface trauma, and no mucosal involvement for forehead, frown line, and crow's feet treatment. Generally the most compatible cosmetic treatment once disease is controlled.
  • Hyaluronic acid filler away from the lips. Cheeks, temples, and chin involve limited puncture trauma, and HA filler can be dissolved with hyaluronidase if a problem develops. Biostimulatory fillers, discussed in the comparison of biostimulatory fillers and hyaluronic acid, are not reversible and deserve more caution in any immune-active patient.
  • Lip filler and perioral work. The lips and the inside of the mouth are the home territory of pemphigus vulgaris. Lip injections pass close to or through the vermilion and can involve the wet mucosa, and a technique that enters through the inner lip should be avoided. Swelling and bruising after injection can obscure an early flare. Many dermatologists would want a long period of oral remission before lip filler, and a patient with any active oral erosions should not have it at all. The same caution applies to resurfacing for lip lines and perioral wrinkles.
  • Non-ablative and vascular lasers. These leave the surface largely intact and heat deeper tissue or blood vessels. They carry less risk than ablative treatment, though heat and post-procedure inflammation still matter.
  • Microneedling, ablative lasers, medium and deep peels, and dermabrasion. These deliberately breach or remove the epidermis over large areas. They sit at the far end of the risk spectrum, and the case for them should be strong, the remission long, and the dermatologist explicitly in agreement. The difference between treatments that wound the surface and those that do not is laid out in the guide to ablative and non-ablative laser resurfacing. A deep phenol peel is a poor fit for most patients with a history of pemphigus.
"In pemphigus, the most dangerous cosmetic procedure is not necessarily the largest one. A full-face ablative laser asks a fragile epidermis to rebuild itself across the entire face at once, while a facelift asks it to heal along a few well-protected lines."

Three practical issues apply to almost any facial treatment. First, herpes simplex. Cold sore reactivation is a known trigger for complications after perioral procedures in anyone, and in pemphigus, herpes infection of existing erosions is a recognized complication that can mimic or provoke a flare. Antiviral prophylaxis is standard before perioral resurfacing and is worth discussing before lip work. Second, the pigment left behind. Pemphigus erosions usually heal without scarring but often leave patches of darker or lighter skin, especially in medium and darker skin tones. Treating that residual discoloration with the tools described in the piece on lasers for sun spots and pigmentation should wait, and the first steps are usually topical: sun protection, time, and gentle lightening agents. Third, the sun. Ultraviolet exposure has been reported to flare pemphigus, particularly pemphigus foliaceus, which favors the face and scalp. Any post-procedure skin plan needs strict photoprotection.

Dental work deserves a mention because it is often scheduled alongside facial plans. Oral hygiene is harder with painful erosions, gum disease worsens, and dental procedures themselves can irritate the mucosa. The general sequencing questions covered in the piece on braces, veneers, implants, and facial cosmetic surgery apply here with an extra rule: major dental treatment, like elective surgery, goes better during remission, and the dentist should know the diagnosis.

Surgery with fragile skin: tape, intubation, steroids, and wound healing

The short answer: Surgery in a patient with controlled pemphigus is often possible, but the team must protect the skin and mouth from shear and adhesives, plan the airway with the mucosa in mind, account for current and recent steroid use, and watch incisions closely for delayed healing and infection.

Surgical incisions are a different kind of wound from resurfacing. They are narrow, closed in layers, and protected, and the epidermis needs to bridge only a fine line. That is why many patients with well-controlled pemphigus can undergo a deep-plane facelift, a blepharoplasty, breast surgery, or body contouring with good results. The risks are concentrated in the details around the incision rather than the incision itself.

The details that matter:

  • Adhesives and friction. Because of the Nikolsky phenomenon, ordinary surgical tape, adhesive dressings, ECG electrodes, and the act of pulling them off can strip the epidermis in a patient with any disease activity. Silicone-based tapes and dressings, nonadhesive wraps, careful padding at pressure points, and gentle removal are sensible precautions even in remission. Compression garments after liposuction or a tummy tuck should be fitted to avoid rubbing and shear.
  • The airway. Pemphigus vulgaris can involve the throat and larynx, sometimes without obvious symptoms beyond hoarseness. Intubation, suction catheters, oral airways, and even a face mask held firmly on the skin can cause erosions and bleeding in active disease. Anesthesiologists who know the diagnosis typically use generous lubrication, gentle technique, and the least traumatic airway device suitable for the operation, and some will look for laryngeal involvement beforehand if the patient has hoarseness or throat symptoms. The general tradeoffs are covered in the piece on anesthesia choice and the operative plan, and this is a case where the anesthesiologist should hear the diagnosis well before surgery day.
  • Steroids and the adrenal glands. Months of prednisone suppress the body's own cortisol production, and that suppression can persist after the dose is lowered or stopped. A patient who has taken significant doses within roughly the past year may need a stress-dose plan around surgery, decided by the anesthesiologist and the prescribing physician. This is separate from the short course of perioperative steroids some surgeons use to limit swelling, discussed in the piece on steroids for swelling after plastic surgery.
  • Wound healing. Chronic corticosteroids impair collagen formation and wound strength, and higher doses raise the risk of slow healing and separation. A patient still taking more than a low maintenance dose of prednisone has a meaningfully higher risk of the problems described in the piece on wound dehiscence after cosmetic surgery. Procedures with long incisions under tension, such as abdominoplasty and lower body lifts, are the most sensitive.
  • Infection. Immunosuppression raises infection risk, and skin that has repeatedly broken down may be colonized with staphylococcus. Decolonization protocols, covered in the piece on staph decolonization before cosmetic surgery, are reasonable to discuss. Any antibiotic choices should be made with awareness of the patient's medications, and drugs with a history of triggering pemphigus in that patient should be avoided.

A word on the nose and eyes. Pemphigus vulgaris can involve the nasal lining, causing crusting and nosebleeds, which is relevant for anyone considering rhinoplasty or septal surgery and for nasal intubation. Eye involvement in pemphigus vulgaris is usually limited to inflammation of the conjunctiva without scarring, unlike mucous membrane pemphigoid, a different blistering disease that can scar the eye. Before eyelid surgery, a patient with any history of eye involvement should have an ophthalmology review.

Rituximab, steroids, and the side effects patients want fixed

The short answer: Rituximab, corticosteroids, and steroid-sparing drugs each affect surgical timing and infection risk, and the visible effects of prolonged steroid treatment, such as a rounded face, fat at the back of the neck, thin bruising skin, and stretch marks, often improve on their own after the dose falls, so cosmetic correction should usually wait.

Rituximab works by depleting B cells, the cells that make the antibodies driving pemphigus. A course is typically given as two infusions two weeks apart, sometimes followed by maintenance infusions, and B cells usually remain depleted for six months to a year. That depletion is the point of the treatment, but it also blunts responses to vaccines and raises infection risk. The drug carries boxed warnings for hepatitis B reactivation and for a rare brain infection called progressive multifocal leukoencephalopathy, and long-term use can lower antibody levels in the blood. For cosmetic planning, the practical questions are when the last infusion was, whether the next one is scheduled, and whether antibody levels are normal. Many clinicians prefer elective surgery to fall in the middle of the interval between doses, after the immediate infusion period and with enough time for healing before the next one, but the timing should be set with the dermatologist. Patients who need vaccines are generally advised to receive them before rituximab rather than after, which is another reason to coordinate calendars.

The other medications:

  • Prednisone. Beyond its effects on wound healing and the adrenal glands, prolonged use raises blood sugar, thins bone, raises blood pressure, and can cause cataracts and mood changes. Bone loss matters for anyone considering facial skeletal procedures or for later life, as discussed in the piece on osteoporosis and cosmetic surgery.
  • Mycophenolate. A common steroid-sparing drug. Whether to hold it around surgery is a judgment call, balancing a modest increase in infection and healing concerns against the risk of a flare. Many dermatologists continue it through minor procedures. It also requires reliable contraception because it harms a developing pregnancy.
  • Azathioprine. Another steroid-sparing option, monitored with blood counts and liver tests. Long-term use increases the risk of skin cancers, particularly squamous cell carcinoma, which makes sun protection and skin checks part of any facial plan.
  • Supplements. Patients sometimes add herbal remedies marketed as immune boosters. Anything that stimulates the immune system is a poor idea in an autoimmune disease, and many supplements also affect bleeding. The standard supplement stop list before surgery applies, with extra caution about products claiming immune effects.

Then there are the changes patients most want fixed. Months of high-dose prednisone produce a recognizable set of features: a fuller, rounder face, fat accumulating at the back of the neck and above the collarbones, abdominal weight gain, thin skin that bruises easily, acne, and purple stretch marks. These are the same features seen in Cushing's syndrome, covered in detail in the piece on Cushing's syndrome and cosmetic surgery. The crucial difference is that when they come from medication, most of them improve as the dose is reduced, often substantially over months. Treating a steroid-rounded face with liposuction or removing a neck fat pad with the approach described in the piece on buffalo hump liposuction while the patient is still on high doses risks operating on a moving target, in tissue that heals poorly. The better plan is to wait until the dose is at maintenance levels or stopped and the face has settled, then reassess what remains. Stretch marks fade in color but rarely disappear, and they are a reasonable target for later treatment once the disease and the skin are stable.

Finally, the emotional context. Pemphigus is a frightening disease to live through. Many patients spent months unable to eat comfortably, endured weight loss and visible lesions, and then coped with the changes caused by treatment. The wish to look like oneself again is entirely reasonable. It is also exactly the moment when a patient may be pressed to act quickly, which is why getting a second opinion from a surgeon who is willing to talk directly with the dermatologist is worth the extra appointment.

The honest summary

Pemphigus vulgaris is rare, but it raises questions that most cosmetic patients never face, because it targets the proteins that hold skin and mucosa together. Its first sign is usually painful mouth erosions that do not heal, and it is often mistaken for gum disease, canker sores, or herpes for months. A patient who mentions persistent mouth sores during a consultation for lips, lasers, or a facelift deserves a referral before a booking. Pemphigus foliaceus, its more superficial cousin, can look like seborrheic dermatitis on the face and scalp, and paraneoplastic pemphigus is a separate, serious disease that needs an oncologic workup.

For a patient with diagnosed pemphigus, the governing principle is timing. Elective procedures belong in documented, sustained remission, including the mouth, ideally on minimal therapy or none, with the dermatologist's explicit agreement. Rituximab has transformed outcomes, with the Ritux 3 trial reporting 89 percent complete remission off therapy at two years compared with 34 percent on prednisone alone, but its B-cell depletion, infection risk, and infusion calendar need to be built into any surgical plan. Procedures that injure the surface across a large area, such as ablative lasers, deep peels, dermabrasion, and microneedling, carry the most theoretical risk, and lip filler deserves particular caution because the lips and mouth are where the disease lives. Neurotoxins and reversible filler away from the lips are generally more compatible. Surgery is often possible, provided the team avoids adhesive tape and friction, protects the airway, plans for recent steroid exposure, and watches healing closely. The visible effects of prolonged steroid treatment frequently improve on their own as doses fall, so the patient who wants them corrected is usually better served by waiting. A patient in stable remission, with a coordinated plan and a surgeon who respects the disease, can often do well. A patient with active erosions needs a dermatologist, not a cosmetic calendar.